SELLAS Life Sciences Group, Inc.
Report Phase 1 top line lymphoma data
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Jun 2023
- Due
- 30 Sep 2023
- Delivered
- September 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We also expect the Phase 1 top line lymphoma data within Q3”
What we found
Evidence strength A What the grades mean
The company announced positive topline data for the relapsed/refractory lymphoma patient group from the Phase 1 dose-escalation trial of SLS009 in September 2023, meeting the Q3 deadline.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2023-11-09
“In September 2023, we announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of SLS009” ✓ confirmed on the page
Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (8 Nov 2023 to 13 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 1 top line lymphoma data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002017 · Corrections policy